Sanofi’s Lemtrada MS Drug Effective in Extension Trial

Sanofi, France’s biggest drugmaker, said its experimental medicine Lemtrada remained effective in patients suffering from multiple sclerosis during the first year of an extension study.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.